For research use only. Not for human consumption. Not medical advice — consult a licensed clinician.

Immune Modulator

Vasoactive Intestinal Peptide (VIP)

Also known as: VIP

Vasoactive Intestinal Peptide (VIP) is a 28-amino acid neuropeptide of the secretin/glucagon family, widely distributed in the CNS and peripheral nervous system. It is a potent vasodilator, bronchodilator, and immunomodulator. Synthetic VIP (aviptadil) has been investigated in clinical trials for COVID-19-associated acute respiratory failure; it is NOT FDA-approved. Intranasal compounded VIP is used off-label in the controversial 'CIRS' (Chronic Inflammatory Response Syndrome) / mold-illness protocol popularized by Ritchie Shoemaker — CIRS is not a mainstream medical diagnosis.

Real-time market data

Pricing for Vasoactive Intestinal Peptide (VIP)

Live vendor pricing, normalized to $/mg so sizes compare fairly — fused with each seller's Merit trust score and latest independent COA purity. Prices refresh daily.

Average price

$9.08/mg

range $3.90–$22.00/mg

Sellers

40

from $36.00

45-day trend

+8.1%

vs 45-day avg $/mg

34 of 40 sellers have a current price· 26 stale listings hidden (not seen in 7 days)

Prices observed from public storefronts (last 24h), normalized to $/mg. "Evidence" is Merit's 0–100 Merit Score, derived only from observable verification evidence (methodology on /about); "Purity" is the latest independent COA. Some buy links are affiliate links — Merit may earn a commission at no extra cost to you, and where a vendor offers one, the code shown gets you a discount at their checkout. Affiliate status never affects price data, ranking, or the Merit Score (full policy on /disclosure). Research use only.

Independent evidence

COAs for Vasoactive Intestinal Peptide (VIP)

19 third-party tests across 9 vendors. Each card links to the full report.

All 19 COAs for Vasoactive Intestinal Peptide (VIP) →
Measured purity 99.1%–99.9% across 11 COAs
Measured purity over time
Aggregated · 3rd-party listing
99.46 %
Apr 2026
ILS Labs Strong · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by Crush Research· batch CRVIP-10-2604-1

Aggregated · 3rd-party listing
99.20 %
Mar 2026
Freedom Diagnostics Moderate · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by Simple Peptide· batch VP5-032026-1

Aggregated · 3rd-party listing
99.72 %
Feb 2026
BioRegen Moderate · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by BioLongevity Labs· batch 31-3-46041

Aggregated · 3rd-party listing
99.27 %
Jan 2026
Janoshik Analytical Limited · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by Mile High Compounds· batch VIP-010-MH-01

Aggregated · 3rd-party listing
99.09 %
Dec 2025
Freedom Diagnostics Moderate · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by Glacier Aminos· batch VIP10GA01

Aggregated · 3rd-party listing
99.88 %
Nov 2025
BioRegen Moderate · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by BioLongevity Labs· batch 31-3-45951

Aggregated · 3rd-party listing
99.80 %
Oct 2025
MDx BioAnalytical Laboratory Strong · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by BioLongevity Labs· batch cmojb76ku0193kirx6m3i9gri

Aggregated · 3rd-party listing
99.65 %
Sep 2025
Janoshik Analytical Limited · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by Skye Peptides· batch VIP25-05-002

Aggregated · 3rd-party listing
99.42 %
Jul 2025
BioRegen Moderate · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by Peptide Partners· batch VP20250511

Aggregated · 3rd-party listing
99.13 %
Jun 2025
MZ Biolabs Moderate · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by Profound Aminos· batch 2025-05-19

Aggregated · 3rd-party listing
99.81 %
Apr 2023
Janoshik Analytical Limited · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by Verified Peptides· batch cmojb6azj012wkirxcsj3o26v

Aggregated · 3rd-party listing
99.57 %
Freedom Diagnostics Moderate · HPLC

For

Vasoactive Intestinal Peptide (VIP)

by Glacier Aminos· batch VIP10GA-02

Aggregated · 3rd-party listing
Jan 2026

Purity not on file

Janoshik Analytical Limited

For

Vasoactive Intestinal Peptide (VIP)

by Mile High Compounds· batch VIP-010-MH-01

Aggregated · 3rd-party listing
Jan 2026

Purity not on file

Janoshik Analytical Limited

For

Vasoactive Intestinal Peptide (VIP)

by Mile High Compounds· batch VIP-010-MH-01

Aggregated · 3rd-party listing
Nov 2025

Purity not on file

BioRegen Moderate

For

Vasoactive Intestinal Peptide (VIP)

by BioLongevity Labs· batch 31-3-45951

Aggregated · 3rd-party listing
Oct 2025

Purity not on file

MDx BioAnalytical Laboratory Strong

For

Vasoactive Intestinal Peptide (VIP)

by BioLongevity Labs· batch cmojb76h30192kirxwdp6g317

Aggregated · 3rd-party listing
Sep 2025

Purity not on file

Janoshik Analytical Limited

For

Vasoactive Intestinal Peptide (VIP)

by Skye Peptides· batch VIP25-05-002

Aggregated · 3rd-party listing
Sep 2025

Purity not on file

Janoshik Analytical Limited

For

Vasoactive Intestinal Peptide (VIP)

by Skye Peptides· batch VIP25-05-002

Aggregated · 3rd-party listing

Purity not on file

TrustPointe Analytics Moderate

For

Vasoactive Intestinal Peptide (VIP)

by Peptide Partners· batch cmojb223b003fkirx4s4gkb1s

Research depth

20 citations indexed for Vasoactive Intestinal Peptide (VIP)

All research on Vasoactive Intestinal Peptide (VIP) →

Study · 2025

Vasoactive Intestinal Peptide (VIP) in COVID-19 Therapy-Shedding of ACE2 and TMPRSS2 via ADAM10

Patients infected with SARS-CoV-2 may develop mild respiratory symptoms but also Acute Respiratory Distress Syndrome (ARDS). Additionally, severe systemic inflammation contributes to morbidity and mortality.

animal · 2025

Vasoactive Intestinal Peptide (VIP) and its Receptors in Adipose Tissue: Implications for Cold Stress Adaptation

Adipose tissue represents an organ that is highly dynamic and contributes toward vital survival events such as immune responses, lactation, metabolism fuel, and thermogenesis.

rct · 2025

Efficacy and Safety of Stapokibart in Non-Allergic Rhinitis With Eosinophilia Syndrome

The goal of this clinical trial is to learn if Stapokibart (CM310) works to treat Non-Allergic Rhinitis with Eosinophilia Syndrome (NARES) in adults. It will also learn about the safety of CM310. The main questions it aims to answer are: Does drug CM310 relieve the symptoms of participants?

Study · 2024

Increased Vasoactive Intestinal Peptide (VIP) in polycystic ovary syndrome patients undergoing IVF

Introduction Polycystic ovary syndrome (PCOS) is a common multifactorial and polygenic disorder of the endocrine system, affecting up to 20% of women in reproductive age with a still unknown etiology.

animal · 2024

The role of vasoactive intestinal peptide (VIP) in atropine-related inhibition of the progression of myopia

Objective This study aimed to investigate the potential involvement of vasoactive intestinal polypeptide (VIP) in myopia development and its contribution to the mechanism of action of the anti-myopia drug, atropine.

animal · 2024

Distribution of vasoactive intestinal peptide (VIP) immunoreactivity in the rat pallial and subpallial amygdala and colocalization with γ-aminobutyric acid (GABA)

The amygdaloid complex, also known as the amygdala, is a heterogeneous group of distinct nuclear and cortical pallial and subpallial structures. The amygdala plays an important role in several complex functions including emotional behavior and learning.